Efficacy Study of Oral Seliciclib to Treat Non-Small Cell Lung Cancer

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Non-small Cell Lung Cancer

In brief

A phase 2 study to evaluate efficacy of oral seliciclib in treating non-small cell lung cancer (NSCLC).

Key facts

Study ID

NCT00372073

Run by

Cyclacel Pharmaceuticals, Inc.

People needed

187

Starts

2006-08-09

Expected to finish

2009-04-07

Last updated by the study team

2021-12-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Adult patients with histologically-confirmed recurrent non-small cell lung cancer have had at least two prior systemic treatment regimens
• Must have measurable disease according to RECIST
• Eastern Cooperative Oncology Group performance status 0-1
• Adequate bone marrow, hepatic and renal function
• Ability to swallow capsules
• At least 3 weeks from prior systemic treatments including investigational anti-cancer therapy, at least 7 days from prior radiation therapy and have recovered from prior toxicities
• At least 3 weeks from major surgery

You may not qualify if…

• Non-small cell cancer histology contains a component of small cell lung cancer
• Previously untreated CNS metastasis or progressive CNS metastasis
• Prior treatment with a CDK inhibitor
• Currently receiving radiotherapy, biological therapy, or any other investigational therapy
• Uncontrolled intercurrent illness
• Having other cancers that have been treated with chemotherapy or biological therapy in the past 5 years with the exception of adequately treated in situ cervical cancer or basal cell skin cancer
• Pregnant or lactating women
• Known to be HIV-positive
• Active hepatitis B and/or hepatitis C infection

Where it is running

• Arizona Cancer Center — Tucson, Arizona, United States
• Pacific Coast Hematology Oncology Group — Fountain Valley, California, United States
• Pasco Hernando Oncology — New Port Richey, Florida, United States
• Rush University Medical Center — Chicago, Illinois, United States
• The University of Chicago — Chicago, Illinois, United States
• University of Maryland, Greenebaun Cancer Center — Baltimore, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Nebraska Medical Center — Omaha, Nebraska, United States
• Nevada Cancer Research Foundation — Las Vegas, Nevada, United States
• VA Sierra Nevada Health Care System — Reno, Nevada, United States
• New Mexico Oncology Hematology Consultants — Albuquerque, New Mexico, United States
• Columbia Presbyterian Medical Center — New York, New York, United States
• Penn State Milton S. Hershey Medical Center — Hershey, Pennsylvania, United States
• University of Pittsburg Cancer Institute — Pittsburgh, Pennsylvania, United States
• The Family Cancer Center — Collierville, Tennessee, United States
• Vanderbilt University Medical Center — Nashville, Tennessee, United States
• Southwest Regional Cancer Center — Austin, Texas, United States
• Center for Oncology Research and Treatment — Dallas, Texas, United States
• East Texas Medical Center — Tyler, Texas, United States
• Danville Hematology Oncology — Danville, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.